Immune Control and Vaccination Against the Epstein-Barr Virus in Humanized Mice

Overview

Journal Vaccines (Basel)

Date 2019 Dec 22

PMID 31861045

Citations 4

Authors

Christian Munz

Affiliations

Soon will be listed here.

Abstract

Mice with reconstituted human immune system components (humanized mice) offer the unique opportunity to test vaccines preclinically in the context of vaccine adjuvant sensing by human antigen presenting cells and priming of human cytotoxic lymphocyte populations. These features are particularly attractive for immune control of the Epstein-Barr virus (EBV), which represents the most potent growth-transforming pathogen in man and exclusively relies on cytotoxic lymphocytes for its asymptomatic persistence in the vast majority of healthy virus carriers. This immune control is particularly impressive because EBV infects more than 95% of the human adult population and persists without pathology for more than 50 years in most of them. This review will discuss the pathologies that EBV elicits in humanized mice, which immune responses control it in this model, as well as which passive and active vaccination schemes with adoptive T cell transfer and with virus-like particles or individual antigens, respectively, have been explored in this model so far. EBV-specific CD8 T cell priming in humanized mice could provide crucial insights into how cytotoxic lymphocytes against other viruses and tumors might be elicited by vaccination in humans.

Citing Articles

Mini-review on the therapeutic vaccines targeting chronic infectious diseases: Evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers.

Woo S, Park P, An T, Fatima M, Moon Y, Lee S Hum Vaccin Immunother. 2025; 21(1):2457187.

PMID: 39957237 PMC: 11834422. DOI: 10.1080/21645515.2025.2457187.

Urgency and necessity of Epstein-Barr virus prophylactic vaccines.

Zhong L, Krummenacher C, Zhang W, Hong J, Feng Q, Chen Y NPJ Vaccines. 2022; 7(1):159.

PMID: 36494369 PMC: 9734748. DOI: 10.1038/s41541-022-00587-6.

Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses.

Chen H, Zhong L, Zhang W, Zhang S, Hong J, Zhou X Viruses. 2021; 13(11).

PMID: 34834989 PMC: 8624110. DOI: 10.3390/v13112184.

Nanotechnology Frontiers in γ-Herpesviruses Treatments.

Granato M Int J Mol Sci. 2021; 22(21).

PMID: 34768838 PMC: 8583734. DOI: 10.3390/ijms222111407.

Therapeutic vaccines for aggressive B-cell lymphoma.

Xu-Monette Z, Young K Leuk Lymphoma. 2020; 61(13):3038-3051.

PMID: 32840404 PMC: 8344075. DOI: 10.1080/10428194.2020.1805113.

References

Gujer C, Murer A, Muller A, Vanoaica D, Sutter K, Jacque E . Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 2019; 3(7):1129-1144. PMC: 6457222. DOI: 10.1182/bloodadvances.2018025536. View

Zayoud M, El Malki K, Frauenknecht K, Trinschek B, Kloos L, Karram K . Subclinical CNS inflammation as response to a myelin antigen in humanized mice. J Neuroimmune Pharmacol. 2013; 8(4):1037-47. DOI: 10.1007/s11481-013-9466-4. View

Heslop H, Ng C, Li C, Smith C, Loftin S, Krance R . Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996; 2(5):551-5. DOI: 10.1038/nm0596-551. View

Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo H, Ivanova A . Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003; 21(4):405-13. DOI: 10.1038/nbt805. View

Al-Samkari H, Berliner N . Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2017; 13:27-49. DOI: 10.1146/annurev-pathol-020117-043625. View

Dunmire S, Grimm J, Schmeling D, Balfour Jr H, Hogquist K . The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLoS Pathog. 2015; 11(12):e1005286. PMC: 4666617. DOI: 10.1371/journal.ppat.1005286. View

Kalchschmidt J, Bashford-Rogers R, Paschos K, Gillman A, Styles C, Kellam P . Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med. 2016; 213(6):921-8. PMC: 4886369. DOI: 10.1084/jem.20160120. View

Gagnaire A, Nadel B, Raoult D, Neefjes J, Gorvel J . Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol. 2017; 15(2):109-128. DOI: 10.1038/nrmicro.2016.171. View

Munz C, Bickham K, Subklewe M, Tsang M, Chahroudi A, Kurilla M . Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000; 191(10):1649-60. PMC: 2193162. DOI: 10.1084/jem.191.10.1649. View

10.

Honeycutt J, Liao B, Nixon C, Cleary R, Thayer W, Birath S . T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest. 2018; 128(7):2862-2876. PMC: 6026008. DOI: 10.1172/JCI98968. View

11.

Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm G, Mautner J . Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006; 203(4):995-1006. PMC: 2118290. DOI: 10.1084/jem.20051287. View

12.

Gregorovic G, Boulden E, Bosshard R, Elgueta Karstegl C, Skalsky R, Cullen B . Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. J Virol. 2015; 89(22):11711-4. PMC: 4645642. DOI: 10.1128/JVI.01873-15. View

13.

Ramiro A, Jankovic M, Eisenreich T, Difilippantonio S, Chen-Kiang S, Muramatsu M . AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004; 118(4):431-8. DOI: 10.1016/j.cell.2004.08.006. View

14.

Antsiferova O, Muller A, Ramer P, Chijioke O, Chatterjee B, Raykova A . Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog. 2014; 10(8):e1004333. PMC: 4148450. DOI: 10.1371/journal.ppat.1004333. View

15.

McHugh D, Caduff N, Murer A, Engelmann C, Deng Y, Zdimerova H . Infection and immune control of human oncogenic γ-herpesviruses in humanized mice. Philos Trans R Soc Lond B Biol Sci. 2019; 374(1773):20180296. PMC: 6501906. DOI: 10.1098/rstb.2018.0296. View

16.

Li Y, Masse-Ranson G, Garcia Z, Bruel T, Kok A, Strick-Marchand H . A human immune system mouse model with robust lymph node development. Nat Methods. 2018; 15(8):623-630. DOI: 10.1038/s41592-018-0071-6. View

17.

Cesarman E . Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol. 2013; 9:349-72. DOI: 10.1146/annurev-pathol-012513-104656. View

18.

Yuling H, Ruijing X, Li L, Xiang J, Rui Z, Yujuan W . EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res. 2009; 69(20):7935-44. DOI: 10.1158/0008-5472.CAN-09-0828. View

19.

Grant M, Bollard C . Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. Blood Rev. 2017; 32(3):203-224. PMC: 5970011. DOI: 10.1016/j.blre.2017.11.004. View

20.

Murer A, Ruhl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O . MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control . mBio. 2019; 10(1). PMC: 6336420. DOI: 10.1128/mBio.01941-18. View